Featured Research

from universities, journals, and other organizations

Researchers Identify Genetic Markers That Predict Efficacy Of Novel Cancer Drug

Date:
May 30, 2008
Source:
University of Southern California
Summary:
Researchers have identified genetic markers in cancer cells that predicted the benefit of a novel cancer drug prior to chemotherapy. Specific genetic profile within tumor cells may indicate increased patient benefit from a particular drug.

Researchers at the University of Southern California (USC) and USC/Norris Comprehensive Cancer Center have identified genetic markers in cancer cells that predicted the benefit of a novel cancer drug prior to chemotherapy.

Researchers looked at the effect of the drug PTK/ZK--a novel therapy designed to inhibit the development of cancer blood vessels--in combination with chemotherapy. The findings suggest that patients with tumors with a specific gene expression profile may benefit most from the incorporation of this drug into their treatment.

"Our research shows that tumor blood vessel formation is critical for tumor growth and that the mechanisms in place controlling tumor blood vessel development are complex," says Peter M. Wilson, senior post-doctoral research fellow at the Keck School of Medicine of USC and lead author of the study. "When we understand how drugs like PTK/ZK work, we can develop treatment strategies to maximize their impact by identifying patients who will benefit most from their use."

The drug regulates angiogenesis, a process of blood vessel formation that provides nutrients and oxygen to cancerous growths, says Wilson. As tumor cells grow, they increase the levels of a key protein called Hypoxia-Inducible Factor 1α (HIF1α) in order to deal with the oxygen depletion. HIF1α results in the tumor cell producing a number of other proteins that assist in promoting blood vessel growth. One of the most important of these is the vascular endothelial growth factor (VEGF) that is released by the tumor and binds to receptors on blood vessels, promoting their growth toward the tumor.

Disrupting the growth of new blood vessels toward a growing tumor will effectively slow tumor growth and spread, he says.

The PTK/ZK was tested in two large clinical trials in patients with metastatic colon cancer. The drug appeared to work well in a subset of patients who had high levels of serum lactate dehydrogenase (LDH)--one of the major targets of HIF1α signaling. Researchers successfully associated genes within this pathway with increased patient benefit from PTK/ZK treatment.

"It is important to note that this is the first study in which we were able to show that gene expression levels (markers) predict efficacy of novel agents targeting tumor blood vessel formation," says Heinz-Josef Lenz, M.D., professor of medicine at the Keck School and the principal investigator on the study. "These markers need to be validated in other clinical trials but are the first step to developing a diagnostic test for clinicians to decide which patients will benefit from inhibitors of the VEGFR."

The data also provides insight into the importance of regulating angiogenesis, and the mechanisms of resistance against new drugs, Lenz says. This information is critical in order to develop more effective and novel drugs using genes as a target.

"The future of colorectal cancer treatment will incorporate such markers in €˜individualized treatment' where a patient will receive an effective chemotherapy based on their own genetic makeup and genetic markers within their tumors," Wilson says.

The study was funded by Novartis Pharmaceuticals.

The results of the study will be presented as an oral presentation on May 31, at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO), held at McCormick Place in Chicago in the clinical science symposium, "Biomarkers in Colorectal Cancer Management." Author and title details are: P.M. Wilson, D. Yang, M.M. Shi, W. Zhang, C. Jacques, J. Barret, K. Danenberg, T. Trarbach., "Intratumoral mRNA Expression of Genes involved in Angiogenesis and HIF1 pathway predict outcomes to VEGFR tyrosine kinase inhibitor (TKI) in patients enrolled in CONFIRM 1 and CONFIRM2."


Story Source:

The above story is based on materials provided by University of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University of Southern California. "Researchers Identify Genetic Markers That Predict Efficacy Of Novel Cancer Drug." ScienceDaily. ScienceDaily, 30 May 2008. <www.sciencedaily.com/releases/2008/05/080529120722.htm>.
University of Southern California. (2008, May 30). Researchers Identify Genetic Markers That Predict Efficacy Of Novel Cancer Drug. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2008/05/080529120722.htm
University of Southern California. "Researchers Identify Genetic Markers That Predict Efficacy Of Novel Cancer Drug." ScienceDaily. www.sciencedaily.com/releases/2008/05/080529120722.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins